Breaking News
March 25, 2019 - Researchers find evidence of Cryptosporidium parasite in Minnesota’s public water systems
March 25, 2019 - Three Clues to Raised Risk of Miscarriage
March 25, 2019 - Structured play helps toddlers self-regulate, altering their life course
March 25, 2019 - Translating horror into justice: Stanford psychiatrist advocates for human rights
March 25, 2019 - HORIBA Medical introduces D-Dimer reagent for Yumizen G hemostasis range
March 25, 2019 - Recurrent pregnancy loss may be caused by sperm DNA damage, finds study
March 25, 2019 - Special Collection tracks development of new diagnostic tests for tuberculosis
March 25, 2019 - Air Force develops genetic test to predict mental performance
March 25, 2019 - To abort or not to abort—making difficult choices alone
March 25, 2019 - Computer vision technology could aid ICU care by spotting movement
March 25, 2019 - IONTAS wins ‘Small Business of the Year’ category at Cambridge News Business Excellence Awards 2019
March 25, 2019 - First postpartum depression drug gets FDA nod
March 25, 2019 - Research Recognition Award will help improve lives of young people with absence epilepsy
March 25, 2019 - Bisphosphonates to treat osteoporosis appears to be beneficial for all women
March 25, 2019 - Dolomite Bio releases new Drop-seq datasets for single-cell RNA sequencing
March 25, 2019 - Hemoglobin A1c blood test may underestimate prevalence of diabetes
March 25, 2019 - Eating leafy green vegetables may help maintain muscle strength and mobility
March 25, 2019 - BMA secures state-backed clinical negligence indemnity scheme for GP trainees
March 25, 2019 - Biohaven Announces Completion of Pre-NDA Meeting With FDA for Oral CGRP Receptor Antagonist Rimegepant
March 25, 2019 - Adding breakfast to classrooms may have a health downside
March 25, 2019 - She Was Dancing On The Roof And Talking Gibberish. A Special Kind Of ER Helped Her.
March 25, 2019 - KNAUER introduces new Sepapure FPLC columns and media for protein purification tasks
March 25, 2019 - Weight loss in obese migraine sufferers can improve their quality of life
March 25, 2019 - Exposure to particulate air pollution may lead to reduced sperm production
March 25, 2019 - Synthetic peptide appears to disrupt inflammation and protect kidneys from nephritis
March 25, 2019 - New guideline focuses on strategies to improve health of older adults with diabetes
March 25, 2019 - Study evaluates prescribing of preventive drugs at the end of life in older adults with cancer
March 25, 2019 - Radial or femoral approaches for PCI are equal in terms of survival in heart attack patients
March 25, 2019 - Study shows how some autoimmune diseases are more closely related than others
March 25, 2019 - Long term opioid medications impacts production of important hormones
March 25, 2019 - FDA Issues Complete Response Letter for Zynquista (sotagliflozin)
March 25, 2019 - CDC researchers report on trends in hospital breastfeeding policies
March 25, 2019 - States Push For Caregiver Tax Credits
March 25, 2019 - Females on ketogenic diet fail to show metabolic benefits in animal model
March 25, 2019 - Modulating stiffness of blood-forming stem cells could facilitate mobilization procedures
March 25, 2019 - Gene editing regulations to be tightened
March 25, 2019 - CPAP treatment can result in weight loss in people with sleep apnea and obseity
March 25, 2019 - Highly attractive businesswomen are considered less trustworthy ‘femmes fatales’
March 25, 2019 - Breast Density Categorization Varies With Screening Modality
March 25, 2019 - Researchers explore link between metal exposure and Parkinson’s symptoms
March 25, 2019 - Later meal timing may contribute to weight gain
March 25, 2019 - Around one in hundred people has autism spectrum condition in China
March 25, 2019 - Research paves way for new standard of care to improve heart’s pump function
March 25, 2019 - Exposure to HIV virus, antiretroviral therapy before birth linked to obesity and asthma-like symptoms
March 25, 2019 - Transgender men preserve their fertility potential after one year of testosterone therapy
March 25, 2019 - Tighter Blood Pressure Control May Prevent Brain Lesions
March 25, 2019 - A reward now or later? Exploring impulsivity in Parkinson’s disease patients
March 25, 2019 - Financial incentives fail to increase completion rates of colorectal cancer screening tests mailed to patients
March 25, 2019 - New research program launched to highlight sexual harassment in academia
March 25, 2019 - Hemoglobin A1c blood test does not detect diabetes in most patients, shows study
March 25, 2019 - Wyss Technology licensed by Sherlock Biosciences to create affordable molecular diagnostics
March 25, 2019 - DWK Life Sciences launches KIMBLE GLS 80 Media Bottle and Multiport Cap System
March 25, 2019 - New study aims to reduce online sexual exploitation of children
March 25, 2019 - Want healthier eating habits? Start with a workout
March 25, 2019 - New approach to prescribing antibiotics could curb resistance
March 24, 2019 - Theravance Biopharma Announces First Patient Dosed in Phase 2b/3 Study of TD-1473 in Patients with Ulcerative Colitis
March 24, 2019 - Prenatal DHA prevents blood-pressure increase from obesity during childhood
March 24, 2019 - Combined immunosuppression may be effective, safe in treating older patients with Crohn’s disease
March 24, 2019 - GSK sells health drinks arm, buys US cancer treatment firm
March 24, 2019 - Bacteria and innate immune factors in birth canal, cervix may be key to predicting preterm births
March 24, 2019 - IgG antibodies play unexpected role in atherosclerosis
March 24, 2019 - Sounds and vibrations are quite similar for the brain, finds new study
March 24, 2019 - Practices for Reducing COPD Hospital Readmissions Explored
March 24, 2019 - Could an eye doctor diagnose Alzheimer’s before you have symptoms?
March 24, 2019 - Enzyme inhibitor stops inflammation and neurodevelopmental disorders in mouse models
March 24, 2019 - Walk, Dance, Clean: Even a Little Activity Helps You Live Longer
March 24, 2019 - Americans used less eye care in 2014 versus 2008
March 24, 2019 - Study finds link between depression in 20s linked to memory loss in 50s
March 24, 2019 - New tool helps physiotherapy students to master complex fine motor skills
March 24, 2019 - The AMR Centre secures £2.3m funding boost
March 24, 2019 - Study examines effects of taking ondansetron during first trimester of pregnancy
March 24, 2019 - Researchers identify a more effective treatment for cancer
March 24, 2019 - Open-source solution for multiparametric optical mapping of the heart’s electrical activity
March 24, 2019 - New nanotechnology approach shows promise in treating triple negative breast cancer
March 24, 2019 - Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain
March 24, 2019 - Maternal deaths following C-section 50 times higher in Africa compared to high-income countries
March 24, 2019 - Apple watch could detect irregular heart beat says study
March 24, 2019 - Queen Mary University of London’s BCI boosts radionuclide imaging capabilities with MILabs VECTor technology
March 24, 2019 - Girls should be encouraged to gain more ball skills, shows study
March 24, 2019 - Acute doses of synthetic cannabinoid can impair critical thinking and memory
Single-cell analysis reveals how melanoma cells resist immunotherapy

Single-cell analysis reveals how melanoma cells resist immunotherapy

image_pdfDownload PDFimage_print
Single-cell analysis reveals how melanoma cells resist immunotherapy
Credit: Broad Institute of MIT and Harvard

Unleashing the immune system to fight tumors—an approach enabled by immunotherapy—has led to remarkable outcomes in some cancer patients, but in many more, cancer cells evade the treatment and continue to spread. Now, a team led by researchers from Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute has identified a gene expression pattern that human melanoma cells use to resist immunotherapy, and demonstrated a combination therapy approach that could overcome this resistance.

The paper, published today in Cell, appears alongside a companion immunotherapy study led by a separate research team from Broad Institute and Massachusetts General Hospital.

“With additional data, we hope that the methods and specific combination therapy identified in our study could have a real benefit for patients,” said co-senior author Benjamin Izar, an instructor in medicine and melanoma oncologist at Dana-Farber Cancer Institute and postdoctoral fellow at the Broad Institute. He and Aviv Regev, director of the Klarman Cell Observatory at the Broad Institute, professor of biology at MIT, and an HHMI investigator, are co-senior authors on the paper.

“Our team has mapped out a high-resolution landscape of immunotherapy-resistant melanoma,” added Regev. “We’ve discovered a gene expression program that can help predict resistance to immunotherapy before treatment even begins, and a potential way to reverse this program in order to delay or counter that resistance.”

Using single-cell RNA sequencing data, the researchers analyzed thousands of melanoma cells from more than 30 melanoma patients, half of which had exhibited resistance to immunotherapies. The team identified a distinct gene expression pattern that correlated with reduced T cell presence in the tumor and other features of immunotherapy resistance.

By measuring the levels of this “resistance program” before treatment, the team could predict how tumors would respond to immunotherapy—thereby addressing a major clinical challenge in the field of immuno-oncology. This analysis was done in larger independent cohorts of melanoma patients, assembled in collaboration with colleagues at Massachusetts General Hospital and the University of Essen in Germany. And in another patient cohort, the group showed that cancer cells further amplify this program when exposed to immunotherapy.

The resistance program included signals that are hallmarks of immune system evasion. Abnormal cells typically have substances on their surfaces, called antigens, that enable T cells to home in and destroy them. But the resistant tumor cells are able to reduce their antigen levels and hide from the immune system. They also reduce the enzymes attacked by the T cells, rendering an assault ineffective if it does occur. Other genes expressed in this program include those that cause cells to unduly proliferate.

“We found that multiple immune evasion mechanisms, and other hallmarks of cancer growth, are strongly co-regulated with each other in this resistance program,” said Livnat Jerby, a postdoctoral fellow in Regev’s lab and first author on the paper. “Certain mutations in these pathways have already been reported to confer immunotherapy resistance, but here we show that there is a shared regulatory program controlling their expression.”

Once the researchers understood this molecular strategy, they began exploring ways to suppress it and sensitize melanoma tumor cells to immunotherapy. Mining data across hundreds of human cell lines, the team predicted that a class of cancer drugs called CDK4/6 inhibitors, which are already known to suppress cell proliferation, could in part reverse the resistance program in cells.

In a mouse model of extremely immunotherapy-resistant melanoma—which expressed the newly discovered resistance program at high levels—the CDK4/6 inhibitors dramatically improved responses to immunotherapy, and the combination approach significantly slowed or eradicated tumors in roughly half the mice.

“It’s unclear what all of CDK4’s activities might actually be, but our data indicate that it could be a ‘master regulator’ of this resistance program,” said Jerby.

Based on this work, the researchers are pursuing a clinical trial to further test their findings. “Our work, along with that of colleagues studying the effects of CDK4/6 inhibitors in breast cancer and other diseases, provides a rationale for exploring combination therapy with immune checkpoint inhibitors,” said Izar. “It’s exciting to see that our work may actually translate back into the clinic and make a difference for patients with resistant melanoma.”


Explore further:
Specific CD8 T cell states may indicate response to immune checkpoint therapy for melanoma

More information:
Livnat Jerby-Arnon et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade, Cell (2018). DOI: 10.1016/j.cell.2018.09.006

Journal reference:
Cell

Provided by:
Broad Institute of MIT and Harvard

About author

Related Articles